dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Vargas Accarino, Elena |
dc.contributor.author | Torrens Buscató, Maria Margarita |
dc.contributor.author | Salcedo Allende, Maria Teresa |
dc.contributor.author | Martínez Campreciós, Joan |
dc.contributor.author | Torres Pérez, Gloria |
dc.contributor.author | Bermúdez Ramos, María |
dc.contributor.author | Bilbao Aguirre, Itxarone Izaskun |
dc.contributor.author | Guerrero Murillo, Mercedes |
dc.contributor.author | Serres Créixams, Xavier |
dc.contributor.author | Merino Casabiel, Xavier |
dc.contributor.author | Rodríguez Frias, Francisco |
dc.contributor.author | Quer Sivila, Josep |
dc.contributor.author | Minguez Rosique, Beatriz |
dc.contributor.author | Gregori Font, Josep |
dc.contributor.author | Higuera Urbano, Monica |
dc.date.accessioned | 2022-11-08T13:03:43Z |
dc.date.available | 2022-11-08T13:03:43Z |
dc.date.issued | 2022-08-11 |
dc.identifier.citation | Higuera M, Vargas-Accarino E, Torrens M, Gregori J, Salcedo MT, Martínez-Campreciós J, et al. Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management. Cancers. 2022 Aug 11;14(16):3875. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/8415 |
dc.description | Biomarkers; cfDNA; Liquid biopsy |
dc.description.abstract | Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient’s outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;14(16) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Fetge - Càncer - Tractament |
dc.subject | Àcids nucleics - Anàlisi |
dc.subject | Fetge - Càncer - Aspectes genètics |
dc.subject.mesh | Carcinoma, Hepatocellular |
dc.subject.mesh | /therapy |
dc.subject.mesh | Sequence Analysis, DNA |
dc.subject.mesh | Cell-Free Nucleic Acids |
dc.title | Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers14163875 |
dc.subject.decs | carcinoma hepatocelular |
dc.subject.decs | /terapia |
dc.subject.decs | análisis de secuencias de ADN |
dc.subject.decs | ácidos nucleicos libres de células |
dc.relation.publishversion | https://doi.org/10.3390/cancers14163875 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Higuera M, Torrens M, Torres G] Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Vargas-Accarino E, Martínez-Campreciós J] Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gregori J] Grup de Recerca en Hepatitis Viral, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Salcedo MT] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. [Bermúdez-Ramos M] Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Bilbao I] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Guerrero-Murillo M] Grup de Recerca en Hepatitis Viral, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Serres-Créixams X, Merino X] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rodríguez-Frías F] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Quer J] Grup de Recerca en Hepatitis Viral, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Mínguez B] Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 36010868 |
dc.identifier.wos | 000846067900001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI18%2F00961 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F00714 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/FI18%2F00027 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |